Breast cancer

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

This pilot study tests a device that uses short, high-frequency electrical pulses to shrink or destroy soft tissue tumors in people with metastatic breast cancer. The trial will enroll 20 adults with tumors near the skin that are at least 1 cm but no larger than 5 cm. The main go…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This study compares two treatments for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low genetic risk of returning. One group gets standard hormone therapy plus a targeted pill (ribociclib), while the other gets chemotherapy first, then the sam…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This phase 3 trial is testing whether adding the targeted drug ribociclib to standard hormone therapy can help prevent invasive breast cancer from returning in people with HR+ HER2- early breast cancer. About 1,400 participants will receive the combination for up to 3 years. The …

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This phase III trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can prevent breast cancer from returning in people with a specific high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 participants with sta…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

This study is testing whether combining a targeted drug (abemaciclib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a common type of breast cancer (HR+/HER2-). About 31 participants will receive both treatments along with hormon…

Researchers are testing whether dalpiciclib, a targeted cancer drug, combined with toremifene, a hormonal therapy, can slow the growth of advanced HR-positive, HER2-negative breast cancer when used as a first-line treatment. The trial plans to enroll 36 women who have not yet rec…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…

This study tests a technique called systematic margin shaving during breast-conserving surgery for breast cancer. The idea is to remove a thin extra layer of tissue around the tumor right after the main lump is taken out, based on a pathologist's check. Researchers want to see if…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This study is for women aged 51 or older whose breast cancer has returned or who have a new cancer in the same breast. The goal is to see if giving a focused, short course of radiation before surgery is safe and effective enough to allow breast-conserving treatment instead of mas…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…

This phase II trial tests whether adding an experimental drug called INBRX-106 to the immunotherapy pembrolizumab (Keytruda) can shrink tumors in people with stage II or III triple-negative breast cancer before they receive standard chemotherapy. The study will enroll 12 adults w…

Researchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…

This study looks at whether eating a Mediterranean diet (rich in vegetables, fruits, nuts, fish, and olive oil) can improve gut health, quality of life, and treatment outcomes for women with early breast cancer undergoing chemotherapy. About 105 participants will be randomly assi…

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…

This trial tests whether adding an experimental drug called culmerciclib to standard hormone therapy can shrink tumors more effectively in women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. Participants receive either the combination or hormone therap…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This study tests a device called SAVI Scout MD, which uses tiny radar reflectors placed in the breast before surgery to help surgeons locate and remove tumors more precisely. The goal is to see if this method leads to complete tumor removal with clear margins, potentially reducin…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…

This study tests a new drug called BGB-43395 combined with letrozole against standard CDK4/6 inhibitor drugs (abemaciclib, palbociclib, or ribociclib) plus letrozole for people with advanced or metastatic HR+/HER2- breast cancer who have not had prior treatment for advanced disea…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This study tests a new drug called elacestrant against standard hormone therapy in people with a certain type of early breast cancer (ER+/HER2-) that has spread to lymph nodes and has a high chance of returning. About 4,220 participants will be randomly assigned to receive either…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This study compares a new experimental drug, BL-M07D1, to an approved therapy (DS-8201) in people with a common form of advanced breast cancer (HR-positive, HER2-low). The goal is to see if the new drug can delay cancer growth or improve survival. About 120 women aged 18 to 75 wi…

Researchers are testing whether adding stereotactic ablative radiotherapy (SABR) to standard systemic therapy helps people with oligometastatic breast cancer, meaning cancer that has spread to only a few sites. The trial enrolls adults with 1 to 5 metastases in up to two organs. …

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This phase 2 trial tests whether adding cediranib or ceralasertib to olaparib can overcome resistance in BRCA-mutated advanced breast cancer. About 60 participants with HER2-negative, BRCA-positive tumors that have progressed on prior therapy will receive one of the two drug comb…

This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- me…

This phase 3 trial is testing a daily pill called giredestrant in 300 people with ER+/HER2- early breast cancer who had to stop standard aromatase inhibitors due to side effects. The study will track how well patients stick with the treatment, their quality of life, and any side …

Inavolisib treats certain PIK3CA-mutated, HR-positive, HER2-negative breast cancers but can raise blood sugar. Researchers at Tianjin Medical University Cancer Institute and Hospital are studying whether matching blood sugar monitoring and preventive metformin to each patient's r…

This study tests whether a non-invasive ventilation mask (NIPPV) can reduce the need for intubation in cancer patients with respiratory failure. Researchers will compare NIPPV plus standard oxygen therapy to standard oxygen therapy alone in 256 participants. The goal is to see if…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune response to the drug pembrolizumab in people with metastatic or locally advanced triple negative breast cancer. About 30 participants will be randomly assigned to receive either the combinat…

This study follows 138 adults in Bulgaria and Slovenia with HER2-low advanced breast cancer who are taking trastuzumab deruxtecan (T-DXd), a targeted therapy. Researchers will track how long patients go before needing a different treatment or dying. The goal is to see how well T-…

This study compares two types of radiation therapy for women with early-stage breast cancer who have had a lumpectomy. One group receives radiation to the whole breast, the other only to the area where the cancer was removed. Both treatments are given once a day for about one wee…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

Researchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep their cancer from growing. About 1,000 adults whose cancer has spread and who have not had prior…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

Researchers are testing whether adding the drug inavolisib to hormone therapy and the antibody combination trastuzumab plus pertuzumab helps shrink HER2-positive, HR-positive breast tumors before surgery. The trial enrolls 170 patients with early-stage breast cancer that has a PI…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…

Researchers are testing whether treating a few growing spots of metastatic breast cancer with surgery, radiation, or heat ablation while continuing the same systemic drug can keep the cancer under control longer. The trial enrolls people with metastatic breast cancer whose cancer…

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This phase 3 trial is testing whether adding a targeted therapy called Sacituzumab tirumotecan (Sac-TMT) to standard chemotherapy and immunotherapy (pembrolizumab) can better eliminate cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor…

This study tests whether a new quarterly injection of letrozole delivers the same amount of medicine into the body as the standard daily pill. It involves 120 postmenopausal women who have already completed at least 4-5 years of hormone therapy for early breast cancer. The goal i…

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This phase 2 trial is testing whether adding a targeted drug called patritumab deruxtecan to standard immunotherapy and chemotherapy can improve outcomes for people with high-risk early-stage triple-negative or hormone receptor-low positive breast cancer. About 372 participants w…

This early-stage trial tests an investigational cancer vaccine called ITI-5000 in 60 people with stage II-III triple-negative breast cancer who have finished standard treatment. The vaccine uses self-amplifying RNA to teach the immune system to attack cancer cells. The study firs…

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This early-stage trial is testing an investigational drug called SI-B036, a bispecific antibody designed to target cancer cells in people with locally advanced or metastatic breast cancer and other solid tumors. The study aims to find the safest dose and understand how the drug b…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This trial is testing an oral drug called elacestrant in Japanese patients with a specific type of advanced breast cancer (ER+/HER2-) that has a mutation in the ESR1 gene and has progressed after prior endocrine therapy including a CDK4/6 inhibitor. The study aims to see if elace…

This study tests whether combining radiation therapy with three drugs (platinum chemotherapy, adebrelimab, and bevacizumab) can control brain metastases from triple-negative breast cancer. About 58 adults aged 18-70 with this specific type of advanced breast cancer will receive t…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. The trial involves about …

This study is a safety check required by Korean health authorities after capivasertib was approved for breast cancer. Researchers will watch for side effects and see how well the drug works in everyday medical practice. About 130 patients in Korea who are already prescribed the d…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

Researchers are testing whether adding the blood pressure drug olmesartan to dalpiciclib and standard hormone therapy helps women with HR+/HER2- advanced breast cancer. The trial enrolls 40 women aged 18 to 75 with locally advanced or metastatic disease. Everyone receives the thr…

This Phase 1 trial is testing ZOLADEX (goserelin), a hormone-blocking implant, in 88 premenopausal women with HR+/HER2- advanced breast cancer. The goal is to see if it can temporarily shut down ovarian function, which may help control the cancer. Participants receive two injecti…

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

Researchers are testing whether a single, concentrated dose of radiation to the tumor site can replace the usual weeks of daily radiation after breast-conserving surgery. The trial enrolls 250 women with early-stage, low-risk breast cancer that has not spread to lymph nodes. Doct…

Researchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…

This phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a combination of chemotherapy and two immunotherapy drugs can better control metastatic triple-negative breast cancer. About 70 participants will be randomly assigned to receive the vaccin…

This early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…

This study tracks how well freezing breast tumors (cryoablation) works together with hormone therapy for women aged 70 and older with low-risk, early-stage breast cancer. Researchers will follow 400 participants for up to 5 years to see how often the cancer comes back. The goal i…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This early-stage trial tests a new drug called IAM1363 in adults with advanced cancers that have HER2 alterations, including breast, lung, and stomach cancers that have spread to the brain. The study aims to find the safest dose and see if the drug can shrink tumors. About 383 pa…

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …

This study tests whether a combination of two drugs (sacituzumab govitecan and pembrolizumab) given after surgery works better than standard treatments to prevent breast cancer from coming back. It is for people with triple negative breast cancer who still have cancer cells in th…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this ne…

This phase 2 trial tests whether adding the experimental drug evexomostat (SDX-7320) to standard chemotherapy (eribulin) works better than chemotherapy alone for people with metastatic triple-negative breast cancer who also have metabolic dysfunction (like insulin resistance). Th…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has a PIK3CA gene change and has stopped responding to hormone therapy. About 500 participants in China will receive inavolisib as part of their regular care. Rese…

This early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …

This phase 2 trial is testing whether adding a drug called inavolisib to two standard treatments (ribociclib and fulvestrant) can shrink tumors or slow cancer growth in people with advanced hormone-receptor-positive, HER2-negative breast cancer that has a specific genetic change …

This study tests a new drug called GDC-4198, alone or combined with another drug (giredestrant), against a standard treatment (abemaciclib plus giredestrant) in people with advanced ER+/HER2- breast cancer that has worsened after prior CDK4/6 inhibitor therapy. The trial has two …

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage trial tests a new drug called ONC-783 in 20 people with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal is to find a safe d…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This phase 3 trial is testing two oral drugs, camizestrant and ribociclib, as a first treatment for people with ER-positive, HER2-negative advanced breast cancer. The goal is to see if the combination can delay the need for next cancer therapy. About 150 participants will take th…

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This trial tests whether an experimental drug called HER3-DXd, given alone or with olaparib, can safely shrink tumors in people with advanced breast cancer that has progressed after treatment with T-DXd. The study includes two groups: one receiving the combination, the other rece…

This study tests a new oral drug called imlunestrant in premenopausal women with estrogen receptor-positive, HER2-negative breast cancer. Some participants will also receive a drug to suppress ovarian function. The effects on tumor cells and ovaries will be compared with those of…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This study tests two oral drugs, AMXT 1501 and DFMO, given alongside standard treatments for people with advanced solid tumors (breast cancer or melanoma) that have worsened after prior therapies. The goal is to find a safe dose and see if the combination helps shrink tumors or s…

This study tests two different doses of inavolisib combined with fulvestrant in people with a specific type of advanced breast cancer (PIK3CA-mutated, HR-positive, HER2-negative). About 80 participants whose cancer worsened after prior treatment will receive the drug combo. The g…

This early-phase study tests a new drug called IEV407, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer that has stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 194 participants will take p…

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This early-phase trial tests two radioactive drugs, [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642, in people with advanced solid tumors that have a protein called GRPR on their surface. These cancers include certain breast, prostate, and colorectal cancers that have stopped responding …

This Phase 2 trial tests whether adding an antiangiogenic drug to standard chemotherapy helps people with relapsed or metastatic triple-negative breast cancer. Participants receive albumin-bound paclitaxel alone, or combined with either apatinib mesylate (a pill) or bevacizumab (…

This trial tests an experimental drug called FH-006 in 150 people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if FH-006 is safe, tolerable, and can shrink tumors. Researchers will measure how the drug moves through the body and …

This phase 2 trial is testing whether adding a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) to elacestrant works better than elacestrant alone for people with advanced ER+/HER2- breast cancer that has already been treated with a CDK4/6 inhibitor. The study will enro…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study is testing several different drug combinations in people with advanced ER-positive breast cancer that has stopped responding to prior treatments. The trial is designed like an 'umbrella,' allowing new drug combos to be added as they become available. About 316 particip…

This study tests whether adding the drug inavolisib to standard hormone therapy and a CDK4/6 inhibitor can help people with a specific type of advanced breast cancer (PIK3CA-mutated, HR+, HER2-). About 450 adults whose cancer has not been treated yet in the advanced setting will …

This early-phase trial is testing an experimental drug called CT7439, taken as a capsule, in about 50 people with solid tumors that have spread or cannot be removed. The study will first test CT7439 alone, then in combination with other cancer treatments. The main goals are to ch…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This phase II trial is testing whether giving a shorter, stronger course of radiation before breast surgery is safer and works better than giving it after surgery for people with non-metastatic breast cancer. The study will enroll 120 participants with different breast cancer typ…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to se…

This study tests a new, ultra-short radiation schedule for early-stage breast cancer. Instead of the usual 3 weeks, patients receive 5 radiation sessions over one week, with an extra boost to the tumor site given at the same time. The goal is to see if this approach is safe, redu…

This study tests a new drug, RO7771950, designed to reach the brain, for people with HER2-positive breast cancer that has spread to the brain or other organs. About 650 participants will receive either the new drug or an existing drug (tucatinib), both combined with standard ther…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This trial tests whether time-restricted eating (TRE) — a 16:8 fasting schedule — is feasible for patients with HER2-negative breast cancer undergoing neoadjuvant chemotherapy. Participants will follow TRE for 16 weeks while receiving chemo, and researchers will measure how many …

This study tests whether adding tocilizumab, an anti-inflammatory drug, to standard chemotherapy improves outcomes for people with metastatic triple-negative or ER-low breast cancer. Researchers will compare the combination to chemotherapy alone in 168 Black and non-Black patient…

This phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…

This study tests two experimental drugs, camizestrant and atirmociclib, in 24 people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after prior treatment. The main goal is to check safety and how the body processes the drugs, with ea…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 40 adults with advanced breast cancer that has no HER2 protein (HER2-0). Participants get the drug every 3 weeks. The goal is to see if it shrinks tumors and which patients benefit most.

This study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…

This phase 2 trial is testing whether giving a combination of three drugs—neratinib, an aromatase inhibitor (letrozole or anastrozole), and trastuzumab—before surgery can completely eliminate invasive breast cancer in postmenopausal women with ER-positive, HER2-positive breast ca…

This phase 3 trial tests whether a new drug (MK-2870), alone or with another drug (pembrolizumab), works better than standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has worsened after hormone therapy w…

This pilot study tests whether adjusting chemotherapy based on early PET scan results can improve outcomes for people with stage 2 or 3 triple negative breast cancer. Participants receive four cycles of chemotherapy plus the immunotherapy drug pembrolizumab. A PET scan after the …

This study looks at whether adding chemotherapy to standard hormone therapy (which suppresses ovarian function) can better prevent breast cancer from coming back in premenopausal women with early-stage, hormone-sensitive breast cancer. About 3,960 participants will be randomly as…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This phase 3 trial is testing whether 6 months of HER2-targeted therapy (trastuzumab and pertuzumab) works as well as the standard 12 months for people with early-stage HER2+ breast cancer who had a complete response to initial chemotherapy. About 1,500 participants will be rando…

This study tests a new combination of two drugs (saruparib and camizestrant) against standard treatments for advanced breast cancer that is hormone-receptor-positive and HER2-negative. It is for people with inherited BRCA1, BRCA2, or PALB2 mutations. The goal is to see if the new…

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This phase 1 trial tests whether adding the experimental antibody axatilimab to the standard drug olaparib is safe and tolerable for people with HER2-negative breast cancer that has spread and is linked to BRCA1, BRCA2, or PALB2 gene changes. Researchers will enroll about 20 part…

This study tests whether a new treatment called Bria-IMT, given with an immunotherapy drug, helps people with advanced metastatic breast cancer live longer compared to standard chemotherapy. About 404 adults whose cancer has not responded to other treatments will participate. The…

This study is testing whether shorter courses of radiation therapy can work as well as standard treatment for people with breast cancer that has spread to lymph nodes. About 768 participants who have had surgery will receive either a very short (ultrahypofractionated) or moderate…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This trial tests whether adding pyrotinib to the standard pre-surgery drug combination can better shrink HER2-positive breast tumors. Women with early or locally advanced breast cancer receive either the standard combination of pertuzumab, trastuzumab, and docetaxel, or the same …

This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…

This study is testing whether a simple blood test that looks for cancer DNA can help doctors decide when to start a targeted therapy (CDK4/6 inhibitor) in people with intermediate-risk HR+ HER2- breast cancer. About 725 participants will have their blood tested every 3 months for…

This Phase 3 study tests whether a new drug, inavolisib, combined with fulvestrant works better than the current standard alpelisib plus fulvestrant for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). The trial enrolled …

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This trial tests whether an experimental drug called ProAgio, which targets blood vessels that feed tumors, can safely and effectively combine with the chemotherapy gemcitabine for people with metastatic triple-negative breast cancer. The study includes adults who have already tr…

This phase 3 trial tests whether the drug triptorelin can protect the ovaries of adolescents and young adults with cancer who are receiving chemotherapy. Chemotherapy can damage the ovaries, making it hard or impossible to get pregnant later. Triptorelin temporarily pauses ovaria…

This study tests whether combining the drug inavolisib with other treatments can safely shrink or eliminate early-stage breast tumors that have a specific genetic change (PIK3CA mutation). About 60 people with untreated stage II-III breast cancer will receive the drug combination…

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This trial tests an experimental oral drug called MBQ-167 in people with advanced breast cancer who have exhausted standard treatments. The drug targets two proteins, Rac and Cdc42, that cancer cells use to grow and spread. Researchers are looking for the highest safe dose and ch…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This phase 2 trial is testing whether using a biomarker test (MammaPrint/BluePrint) to guide treatment choices can improve outcomes for people with early-stage HER2-positive breast cancer. Participants receive standard chemotherapy (paclitaxel, nab-paclitaxel, or docetaxel) combi…

This trial tests whether a personalized exercise program, done at home before breast cancer surgery, can improve physical fitness and influence the body's immune and inflammatory responses. Women with newly diagnosed luminal B or triple-negative breast cancer who are about to rec…

This trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…

This study looks at whether adding a tumor bed boost to standard whole breast radiation after breast-conserving surgery helps women with HER2-positive breast cancer. It will track recurrence, survival, and side effects over seven years. The goal is to see if the extra radiation d…

Researchers are testing whether a small implantable marker called Magseed, along with a handheld magnetic probe called Sentimag, can help surgeons locate and remove a specific axillary lymph node in breast cancer patients who have had chemotherapy before surgery. The study enroll…

This study is testing whether a breath test can detect breast cancer in women aged 40 to 74. Researchers will collect breath samples from over 5,000 women before their standard biopsy or MRI and compare the chemical patterns between those found to have cancer and those who do not…

Researchers are testing a new PET imaging tracer called 18F-HER2 Affibody to see how well it detects HER2-expressing breast cancer. The study includes 40 adults with confirmed or suspected HER2-positive breast cancer. Participants receive the tracer and then undergo a PET scan. T…

Researchers compare two tracers, indocyanine green (ICG) and blue patent dye, for locating lymph nodes during targeted axillary dissection in breast cancer patients who have received chemotherapy before surgery. The trial measures how often each tracer successfully identifies the…

This study is testing a new 3D automated ultrasound system called ATUSA to see how well it can image suspicious breast lesions. Up to 800 women with suspicious findings on standard imaging will get an ATUSA scan before their biopsy. The goal is to collect images and compare them …

This study looks at whether adding an MRI to the yearly mammogram can help find breast cancer earlier in women with dense breasts. Participants will have a mammogram and a risk score calculated from it. Those with a high risk score will be offered an MRI. The goal is to see if th…

Researchers are testing a system called Magseed Pro and Sentimag Gen3 to help surgeons find breast tumors and suspicious lymph nodes during surgery. The study enrolls 224 adults with breast cancer who need these areas marked and removed. Doctors place a small magnetic marker into…

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

The COGNITION study is a molecular diagnostic platform that collects tumor and blood samples from up to 2,000 adults with early breast cancer, including those receiving chemotherapy before surgery. Researchers perform comprehensive genomic sequencing on samples taken before and a…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

This early-stage trial tests a new radioactive tracer called [68Ga]Ga DOTA-5G for PET/CT scans in 30 people with metastatic lobular breast cancer. The goal is to see if it can find cancer lesions better than current methods and to check its safety. Participants receive one inject…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…

This study tests a new imaging agent called pHLIP ICG that makes breast cancer cells glow during surgery. The goal is to help surgeons see and remove all cancerous tissue more accurately. The trial involves 55 adults with early-stage breast cancer who have not had prior treatment…

Researchers are developing a blood test that uses DNA methylation patterns and machine learning to detect multiple types of cancer at an early stage. The PROFOUND study collects blood samples from people newly diagnosed with cancer and from people without a confirmed cancer diagn…

Researchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…

This study is testing a new blood test that uses laser technology and artificial intelligence to help doctors tell apart high-risk and low-risk breast cancer patients. About 330 people with breast cancer will give a blood sample before treatment. The test looks at tiny particles …

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This study tests whether a radioactive tracer called 18F-S16/T807 can help diagnose tau-related brain diseases. Tau is a protein that builds up abnormally in conditions like Alzheimer's and other neurodegenerative disorders. Researchers will give 500 adults a single injection of …

This study tests whether PET/CT scans using two radioactive tracers, 18F-92/AV45 and 11C-PIB, can detect beta amyloid buildup in the brain. Researchers will enroll 500 adults with suspected or known neurodegenerative diseases linked to amyloid. Each participant receives one injec…

This study is testing a special type of PET/CT scan that looks for a protein called PD-L1 on cancer cells. The goal is to see if this scan can find tumors and their spread more accurately than standard imaging. About 500 adults with suspected or known PD-L1-related cancers will r…

This trial tests whether an injected tracer called HED, seen on PET/CT or MRI scans, can help diagnose diseases of the sympathetic nervous system, the part of the body that controls automatic responses like heart rate and blood pressure. Researchers will scan 500 adults who have …

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study enrolls 400 women at high risk for breast cancer to see if a shorter, abbreviated MRI scan works as well as a full-length MRI for early detection. Participants will get MRI scans every 6 months. The goal is to develop faster, personalized screening that could make regu…

This study tests whether a special PET/MRI scan using a radioactive tracer (18F-FFNP) can detect early signs that hormone therapy is working in breast cancer. About 53 postmenopausal women with a certain type of breast cancer will get the scan before and after taking anastrozole …

This study is testing a new blood test, called Syantra DX Breast Cancer, to see if it can accurately identify the presence of breast cancer. The test looks for specific genetic markers in the blood that may indicate cancer. Researchers will compare the test results with standard …

This trial tests whether a simplified heart ultrasound is as good as the standard comprehensive exam for detecting heart problems caused by breast cancer treatment. About 250 breast cancer patients will be randomly assigned to one of the two monitoring approaches. The study also …

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to …

This study tests whether taking a daily statin (rosuvastatin) for one year can safely prevent life-threatening blood clots in people with cancer. Current clot-preventing drugs raise bleeding risks, so a safer option is needed. The trial will enroll 4,000 adults with newly diagnos…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study compares two approaches for breast cancer patients who still have cancer in their sentinel lymph node after chemotherapy: removing the underarm lymph nodes (surgery) or treating them with radiation. The goal is to see if radiation can reduce the risk of arm swelling (l…

Researchers test whether an AI-supported mobile app helps breast cancer patients manage chemotherapy symptoms, feel more confident, and enjoy a better quality of life. Seventy women receiving chemotherapy for the first time join the study. Half use the app to report daily symptom…

This study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…

Researchers are studying whether a supervised exercise program can protect the heart and improve fitness in women receiving chemotherapy for breast cancer. The trial enrolls women who are scheduled for chemotherapy before or after breast cancer surgery. Participants attend exerci…

This study is testing whether a virtual, 8-session group therapy program can help cancer patients find meaning and reduce emotional distress. Researchers at MD Anderson Cancer Center will enroll 72 adults with a history of cancer. Participants will attend weekly 90-minute session…

This study looks at whether combining resistance and aerobic arm exercises can improve arm strength, function, and quality of life in breast cancer patients. About 40 women who are at least 15 months past surgery and not currently active will participate. The goal is to find bett…

This phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …

This trial tests whether personalized acupuncture—chosen together by the patient and clinician—can ease psychosomatic symptoms like anxiety, depression, sleep problems, and fatigue in women with breast cancer. Participants are divided into groups based on their symptom patterns a…

This pilot study tests whether a nurse-led, group-based virtual coping program called RESTORE is feasible and acceptable for people who have finished treatment for triple-negative breast cancer. The program teaches skills like problem-solving, relaxation, and mindfulness to help …

This study tests whether doing physiotherapy and using a mechanical stimulation device before breast reconstruction surgery can reduce shoulder pain and improve movement afterward. About 72 women scheduled for a specific type of breast reconstruction (using a back muscle flap) wi…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…

This study is testing whether a mobile app called Mighty Pro can help young women with breast cancer feel less distressed. The trial will include 120 women aged 18 to 45 who are patients at a specific cancer center. Participants will use the app for 26 weeks, and researchers will…

Chemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…

This study tests whether an artificial intelligence (AI) app can improve quality of life, anxiety, and depression in people with cancer who are already receiving psychotherapy. About 60 participants will be randomly assigned to either get the AI app alongside their usual therapy …

This study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…

This study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…

This pilot study tests a 4-week personalized exercise program for people aged 70 and older who are about to have cancer surgery. Participants follow daily exercises at home using a smartphone app. The goal is to see if this approach improves their physical fitness before the oper…

This study compares standard palliative radiation for lung tumors with a newer, more focused technique that delivers a higher dose while sparing the esophagus. The goal is to improve or maintain quality of life by better controlling symptoms and reducing side effects. About 141 a…

Cancer treatment often leaves patients with a deep, lasting tiredness that few treatments can fix. Researchers are testing whether guarana, a caffeine-rich Amazonian plant, can reduce that fatigue and improve daily life. The study gives 60 people with breast, lung, colorectal, ce…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…

This pilot study is testing a combined program of mobile health exercise and cognitive rehabilitation for older cancer survivors (age 60+) who have concerns about memory or thinking after treatment. The program uses a smartphone app for exercise tracking and group workshops for b…

This study tests whether using a virtual reality helmet during painful medical procedures (like needle sticks or bone marrow tests) can reduce pain in children with cancer. About 74 children aged 6 to 18 will be split into two groups: one gets standard care plus the VR helmet, th…

This trial tests whether pharmacopuncture, a treatment that injects small amounts of herbal medicine into acupuncture points, can reduce joint pain in women with breast cancer who take aromatase inhibitors. These drugs often cause joint pain, and the study compares pharmacopunctu…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

This phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…

This Spanish trial tests whether a 6-month exercise program (combining resistance and aerobic training) can improve quality of life in 74 early breast cancer patients taking hormone therapy. Half the participants will do the exercise program three times a week, while the other ha…

This study tests a 4-month coaching program called SONATA that helps older adults (age 60+) with advanced cancer build a support network of family and friends. The goal is to see if this social support makes it easier to stick with treatment and feel better. About 330 patients an…

This study tests whether a walking program and cognitive rehabilitation exercises can improve memory and thinking in people aged 65 and older who have finished cancer treatment. Forty participants will be randomly assigned to one of four groups: exercise only, cognitive training …

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This study tests whether using a special dye (ICG) to map the arm's lymph vessels can make daily arm massage more effective at preventing lymphedema (swelling) after breast cancer surgery. 30 women will be randomly assigned to either ICG-guided massage or traditional massage, and…

This study tests an online, therapist-guided program to help cancer survivors who have anxiety, depression, or fear of cancer returning. About 400 adults in Sweden who finished cancer treatment at least 6 months ago will take part. The goal is to see which parts of the 10-week on…

This study tests whether a community-based exercise program can improve memory, attention, and brain health in women who have had breast cancer. About 160 survivors, aged 50 and older, will either take part in aerobic exercise or health education sessions. The goal is to see if p…

This trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…

This study tests a nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see …

This study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…

This early-phase study tests whether psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce fear of cancer returning in 20 women with early-stage breast or ovarian cancer who are currently in remission. Participants receive a moderately high d…

This study looks at whether a computer-assisted vacuum procedure to remove blood clots from the lungs is safe and improves quality of life for cancer patients with a moderate-risk pulmonary embolism. About 25 adults with cancer and a confirmed clot in a major lung artery will tak…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

This study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …

This pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…

This study tests a laser treatment for vaginal dryness in breast cancer survivors. Many survivors experience this side effect from cancer treatments like chemotherapy or hormone therapy. The trial will compare the laser to no treatment in 250 women to see if it improves symptoms.

This study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…

This study tests whether a single early meeting with a psycho-oncology counselor can reduce anxiety and depression and improve quality of life in people recently diagnosed with cancer. About 148 patients will be randomly assigned to either receive this counseling plus standard ca…

This study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…

This study tests if electroacupuncture or auricular acupressure (ear pressure) can reduce joint pain caused by hormone therapy in breast cancer survivors. 200 women will be split into three groups: electroacupuncture, ear acupressure, or a waitlist control. The goal is to see if …

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This study tests whether a tailored coaching program can help adolescents and young adults (ages 15-24) with cancer take their oral medications as prescribed. Participants will work with a coach over four sessions to identify and overcome barriers to adherence, using an electroni…

This study tests two types of nerve blocks to see which one works better for pain after breast cancer surgery. 50 women having a mastectomy will get either a newer or a standard block. The goal is to find a way to reduce the need for strong painkillers like morphine and help pati…

This study tests whether a specific nerve block (SPSIP block) can reduce pain and the need for strong painkillers after mastectomy and lymph node removal. About 50 women with breast cancer will receive either the nerve block or a placebo before surgery. The goal is to improve rec…

This trial tests a program that screens cancer survivors for fear of recurrence and refers those who need help to psychological services. The program is being rolled out in cancer clinics in Hong Kong, with nurses trained to identify at-risk patients. Researchers will measure how…

This study tests whether a virtual exercise program with peer support helps older adults (60+) with cancer become more active and feel better. Participants are matched with a peer and receive guidance from exercise professionals or just peer support, compared to usual care. Over …

This study tests a virtual group lifestyle program for women with metastatic breast cancer. The goal is to see if more support helps them stick with healthy habits like diet and exercise. One hundred women will take part, and researchers will track safety and how well they follow…

This pilot study tests a remotely delivered physical activity program designed to help breast cancer survivors increase their weekly exercise. Participants are assigned to either an affect-based or effort-based exercise prescription and receive coaching sessions. Those who are no…

This trial tests a stepped-care program to help cancer survivors manage fear of their cancer returning. The program starts with an online intervention called eConquerFear, which teaches strategies to control worry and accept uncertainty. If needed, participants receive additional…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…

This study tests whether prolonged overnight fasting, exercise, or both can reduce fatigue in women with advanced breast cancer who are taking CDK4/6 inhibitors with endocrine therapy. Participants will follow a 12-week program of fasting for 12-14 hours overnight, an exercise ro…

This trial tests whether a topical blend of essential oils can reduce the painful, tingling, or numb sensations caused by chemotherapy-induced neuropathy in breast cancer patients treated with paclitaxel. The study enrolls women with bothersome nerve symptoms that standard medica…

This trial tests whether water-only fasting for 24 to 48 hours around each chemotherapy session can help people with early-stage breast cancer tolerate treatment better. Participants will fast during four cycles of standard chemotherapy, either before or after surgery. The study …

This trial tests whether a 12-week slow jogging program can help breast cancer survivors sleep better, feel less tired, and enjoy a better quality of life. Women who have finished primary treatment for hormone receptor-positive breast cancer will either jog slowly three times a w…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …

This study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study is testing whether a less invasive procedure called target axillary dissection (TAD) can accurately check for cancer spread in the lymph nodes of people with locally advanced breast cancer after chemotherapy. The goal is to see if TAD can replace more extensive lymph n…

This study is testing an online tool called MyMammogram that helps women ages 39-49 decide whether to get a mammogram. The tool also shares the woman's risk and preferences with her doctor before the visit. The goal is to see if this approach works well in rural healthcare settin…

Researchers at Portsmouth Hospitals NHS Trust and the University of Portsmouth want to know whether they can measure breast biomechanics in women treated for early breast cancer. The study includes 45 women who have had surgery, with or without radiotherapy, for cancer in one bre…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study follows 100 women with early-stage breast cancer who are receiving standard chemotherapy or anti-HER2 therapy. Researchers will use heart ultrasounds and blood tests to look for early signs of heart damage. The goal is to find better ways to detect cardiac side effects…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study tests whether a video and personal guidance can help Black, Latinx, and older adults with cancer get genetic testing. Genetic testing is often needed to join precision cancer trials. The goal is to make trial enrollment more equitable. About 210 people with gastrointes…

This study is building an AI tool called ACTIVATE that scans electronic health records to find cancer patients who may be eligible for clinical trials. Researchers will test whether sending alerts to doctors increases the number of patients starting trials. The goal is to make it…

This study aims to understand why breast cancer risk and outcomes vary among different people. Researchers will collect blood, tissue, and survey data from 800 adults in South Florida, including those with suspicious breast findings or newly diagnosed breast cancer. By analyzing …

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

Surgeons use imaging-guided techniques to locate breast tumors they cannot feel, aiming to remove the cancer completely while sparing healthy tissue. This large observational study compares several methods, including wire-guided localization, intraoperative ultrasound, magnetic s…

This study looks at how the timing of a blood test that detects tumor DNA (ctDNA) affects understanding of prognosis and treatment choices in people with advanced HR+/HER2- breast cancer. Researchers will follow 400 participants to see how ctDNA levels and gene mutations relate t…

This study is testing a new PET-CT scanner that takes high-resolution images of tissue removed during cancer surgery. Researchers want to see if these images match lab results and help surgeons make better decisions. The study will include 850 people with prostate, breast, head a…

This international registry follows people who took part in GBG clinical trials for early breast cancer, collecting health information long after those trials end. Researchers track survival, late side effects, and issues related to pregnancy, fertility, and quality of life. The …

Researchers are comparing three ways to check lymph nodes after chemotherapy in people with breast cancer that had spread to the lymph nodes but turned negative with treatment. The study follows 3,000 patients across multiple countries who receive either full lymph node removal, …

This study tracks 125 cancer patients receiving standard chemotherapy and radiation to understand why they feel tired. Researchers will collect blood, stool, and survey data before, during, and after treatment. The goal is to find patterns that could help predict and manage fatig…

This study is testing an educational program designed to help racial and ethnic minority cancer patients make informed decisions about joining clinical trials. The program involves watching short videos and talking with a patient navigator. Researchers will measure changes in pat…

This study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…

Researchers are testing whether breast cancer patients who give consent digitally can reliably report complications after surgery using questionnaires. The study includes 50 women with early invasive breast cancer who are having breast-conserving surgery and a sentinel lymph node…

This study is testing whether a probiotic called BIOHM can change the community of bacteria and fungi (the microbiome) in the breast and gut of people with breast cancer. Researchers will measure certain biomarkers in 100 participants to see if the probiotic has an effect. The go…

Researchers are studying whether blood and tissue samples can show when metastatic breast cancer stops responding to standard first-line treatment with an aromatase inhibitor and a CDK4/6 inhibitor. The study enrolls women with ER-positive, HER2-negative metastatic breast cancer …

This study enrolls 3,300 women with invasive breast cancer living in 59 North Carolina counties. It aims to understand how tumor biology, healthcare access, and patient behavior together affect outcomes. All participants receive a structured program to improve communication with …

This study is auditing a surgical technique called Targeted Sentinel Node Biopsy (TSNB) for breast cancer patients who have a small number of cancer cells in their lymph nodes. The goal is to see if this less invasive procedure can accurately identify cancer spread while causing …

This study tests whether a telementoring program called ECHO can improve the quality of palliative care for advanced cancer patients in underserved areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia. Researchers will train local doctors through online clinics and w…

This study tests a program called SUPPORT that helps Black and Latino cancer patients learn about and join clinical trials. The program includes a website and a navigator who guides patients. Researchers will see if this increases the number of patients referred to and enrolled i…

This study is collecting blood samples from 170 people with metastatic breast cancer to look for ESR1 gene mutations, which can make cancer resistant to hormone therapy. Researchers will compare these blood-based results with standard tissue tests. The goal is to better understan…

Some cancer drugs cause rare but serious heart and metabolic problems. This study follows 5,000 cancer patients across several French hospitals who receive a dedicated heart checkup and ongoing follow-up through cardio-oncology programs. Researchers track how many patients benefi…

This study is observing about 800 adults with advanced breast cancer (HER2-positive, low, or ultralow) who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers are tracking how long patients stay on the drug before switching treatment…

This international registry collects data on women who have breast reconstruction with implants placed in front of the chest muscle (pre-pectoral) after mastectomy for breast cancer. Researchers follow participants for surgical complications, aesthetic results, cancer outcomes, a…

This study is testing whether it is safe for women aged 70 and older with small, screen-detected, ER+/HER2- breast cancers to simply monitor the tumor with regular ultrasounds instead of undergoing immediate treatment like surgery or radiation. The main goal is to see how many tu…

This study uses online surveys to explore whether cancer patients and their family members across the European Union have equal access to mental health screening and psychological support. Researchers will analyze responses from 2,000 participants to identify disparities, barrier…

This study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…

Cell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…

This study looks at how platinum-based chemotherapy can cause permanent hearing loss in cancer patients, and whether people from poorer backgrounds are more affected. Researchers will test hearing and thinking skills in 172 patients from North West England before and after treatm…

This study is testing whether a special PET scan (HER2-PET) can predict how well the drug T-DXd works in people with advanced breast cancer. About 100 participants with HER2-positive or HER2-low breast cancer will get the scan before treatment. The goal is to see if the scan can …

This study will map the location of small blood vessels in the chest wall using bony and soft tissue landmarks. The goal is to help surgeons perform partial breast reconstruction more precisely after breast cancer surgery. The study will involve 20 women undergoing elective breas…

Researchers at Lille University are following 350 people, including cancer patients recently diagnosed with breast, gynecological, testicular or digestive cancer, their caregivers, and healthcare professionals. Over one year, participants answer questionnaires about post-traumati…

This study tests a new way to mark the area where a breast tumor was removed, so radiation therapy can be more accurately aimed afterward. About 50 adults with early-stage breast cancer or a precancerous condition called DCIS will take part. The goal is to see if this marking hel…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study looks at whether men and women experience different side effects from cancer immunotherapy. Researchers will track symptoms and quality of life in 100 adults starting standard immunotherapy. The goal is to better understand how sex and gender influence treatment experi…

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study looks at how bacteria inside tumors and the immune cells around them affect how well triple-negative breast cancer responds to chemotherapy and immunotherapy. Researchers will collect tumor, blood, and stool samples from 30 women before and during treatment. They want …

This study follows 700 cancer patients who take blood thinners and are scheduled for surgery or medical procedures. Researchers will track how often major bleeding or clotting events occur within 30 days after the procedure. The goal is to see if current blood thinner management …

This study looks at whether starting with a lower dose of CDK4/6 inhibitor pills (palbociclib or ribociclib) and gradually increasing the dose helps older adults (age 65+) with metastatic breast cancer tolerate side effects better and stay on treatment longer. About 500 participa…

This study follows 400 Chinese women with newly diagnosed breast cancer to see how often thyroid problems occur before and during chemotherapy. Researchers will measure thyroid function and structure at diagnosis and after at least four cycles of anthracycline or taxane-based che…

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…

This study looks back at the records of 800 premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who took the Oncotype DX test between 2013 and 2022. Researchers will compare how different adjuvant treatments affect 5-year invasive disease-free surv…

This study follows post-menopausal women with breast cancer who have stopped taking aromatase inhibitors and denosumab, two medications that affect bone. Researchers will monitor bone turnover markers, fractures, and overall bone health over 24 months through clinic visits and bl…

This study follows 500 women with early-stage invasive breast cancer who had breast-conserving surgery without sentinel lymph node biopsy or other axillary surgery. All participants receive adjuvant radiotherapy as part of their routine care. Researchers will track cancer recurre…

This study tests a decision aid called BREASTChoice in 20 breast cancer patients who had breast surgery. Participants use the tool on their phones and share their thoughts in interviews. Researchers measure how much patients learn about reconstruction options using a knowledge su…

This study aims to screen 450 early-stage breast cancer survivors for prediabetes, diabetes, high cholesterol, and heart disease risk. Participants complete surveys and provide lab results, and those with risk factors are directed to community resources. The goal is to catch and …

This study is building a large registry of up to 200,000 people in the U.S. who have had breast cancer. The goal is to collect a wide range of data—from medical records to personal experiences—that reflects the country's diverse patient population. Researchers will use this de-id…

This study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …

This study looks back at medical records of 250 people with a rare type of breast cancer called apocrine lobular carcinoma. Researchers want to understand how this cancer behaves, what treatments patients received, and how they did over time. No new treatments are tested — the go…

This study is looking at how hormone treatments for breast cancer, called aromatase inhibitors and tamoxifen, affect blood sugar control and diabetes risk in postmenopausal women. Researchers will compare blood sugar measures in women taking these drugs to healthy women not on tr…

This study looks at whether offering money for things like travel, lodging, and childcare helps more people from different backgrounds join cancer clinical trials. Researchers will track enrollment and retention of 1,200 patients who are already in a cancer trial. They will compa…

This study looks at how the location of treatment affects whether people with early-stage HER2-positive breast cancer stick to their therapy plan. Researchers will compare patients who have to travel far for treatment with those who don't. The goal is to see if making treatment m…

This study looks at whether a blood test can find tiny bits of tumor DNA left after breast cancer surgery. It includes 100 women with early-stage breast cancer that spread to 1-3 lymph nodes. The goal is to see if this test can help predict which patients are more likely to have …

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study is creating a registry for people with a rare type of breast cancer called invasive lobular carcinoma that has spread. Researchers will collect data from about 12 participants to develop a new tool that better measures how well treatments are working. The goal is to im…

This study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study looks at whether women with a certain type of breast cancer (hormone-sensitive, HER2-negative, with 1-3 positive lymph nodes and a low RecurIndex score) can safely avoid radiation therapy to the lymph nodes. Researchers will follow 635 participants over time to see how…

This study tests whether tracking changes in infection markers and blood culture results over time can help detect sepsis earlier and monitor treatment in adults with cancer. Researchers will follow 100 patients with suspected sepsis during their hospital stay and for up to 30 da…

This study tests a program that screens cancer patients for emotional distress and refers them to mental health services if needed. It involves 50 English- or Spanish-speaking adults with new solid tumor cancers at Jamaica Hospital Medical Center. The goal is to see if such a pro…

This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …

This study looks at whether exercise after finishing cancer treatment is linked to better outcomes, like longer survival without the cancer coming back. Researchers will analyze data from 1,000 adult cancer survivors at Memorial Sloan Kettering. The goal is to see if those who ex…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study investigates whether adding environmental exposure risk assessments to standard care is useful and acceptable for women at average or high risk of breast cancer, as well as those diagnosed with early-onset breast cancer. Researchers will survey patients and providers a…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This large Swedish study collects tumor samples from 20,000 people with breast cancer to map their genetic profiles. Researchers will analyze RNA and DNA to link gene patterns with patient outcomes, such as survival and response to therapy. The goal is to develop new molecular di…

This study looks at whether medical imaging can predict the growth patterns of liver metastases from colorectal and breast cancer. Researchers will take removed liver tumors and map them in 3D, comparing the tissue details with CT and MRI scans taken before surgery. The goal is t…

This trial tests whether 3D-printed molds, created from radiological images, can guide pathologists to sample the most informative parts of a removed tumor. Currently, sampling is done by eye, which may miss key regions. The study will compare samples taken with the mold to stand…

This study is a large registry that tracks cancer patients who receive both radiotherapy and molecular therapies, such as immunotherapy. The goal is to better understand how these two treatments interact and to identify how often severe side effects occur. By collecting data from…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This observational study is following about 2,400 adults with non-small cell lung cancer or breast cancer to see how biomarkers, including whole-genome sequencing, relate to their outcomes. Participants receive their usual cancer care, and researchers track progression-free survi…